Table 1: Baseline characteristics and lipid levels1.

Demographics and lipids500 mg niacin ER dose
( )
1000 mg niacin ER dose
( )
(%) (%)

Age (years)
 18 to 4079 (11.6)12 (7.8)
 41 to 65516 (75.9)131 (85.1)
 ≥66 85 (12.5)11 (7.1)
Gender
 Male480 (70.6)120 (77.9)
 Female200 (29.4)34 (22.1)
HDL-C mg/dL (both genders)
 <40419 (61.6)87 (56.5)
 40 to 59213 (31.3)59 (38.3)
 ≥6044 (6.5)8 (5.2)
Baseline LDL-C mg/dL
 <130266 (39.1)87 (56.5)
 ≥130178 (26.2)34 (22.1)
 Unknown236 (34.7)33 (21.4)
Baseline TG mg/dL
 <150192 (28.2)60 (39.0)
 ≥150483 (71.0)93 (60.4)
 Unknown5 (0.7)1 (0.7)
Baseline TC mg/dL
 <200301 (44.3)96 (62.3)
 ≥200375 (55.2)57 (37.0)
 Unknown4 (0.6)1 (0.7)
Comorbidities
 Diabetes188 (27.7)41 (26.6)
 Stroke (within 6 months)26 (3.8)10 (6.5)
 Hypertension
 (within 6 months)
46 (6.8)7 (4.6)
 Ischemic heart disease
 (within 6 months)
130 (19.1)32 (20.8)
Medication use
 Prestatin users258 (37.9)64 (41.6)
 Prefibric acid users82 (12.1)12 (7.8)
Persistence
 Average persistence (days)193.6192.1
 ≥365 days persistence79 (11.6)17 (11.0)
 <365 days persistence601 (88.4)137 (89.0)

Lipid levels were measured within six months prior to any niacin ER use. Definition of lipids: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol.